The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

AnaptysBio announces positive results from phase 2b trial of rosnilimab to treat rheumatoid arthritis: San Diego Thursday, June 5, 2025, 18:00 Hrs [IST] AnaptysBio, Inc., a clinic ...

Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month​ blinded treatment period Favorable safety and tolerability, particularly ...

A breakdown of how memory B, T, and innate cells remember past infections and how this insight powers vaccines and immunotherapies.

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space.

Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

This study provides important findings on the neural circuits underlying dishabituation of the olfactory avoidance response in Drosophila. The data as presented provide solid evidence that the ...

During cell-to-cell spread, HIV-1 protease activity triggers CARD8 inflammasome activation and IL-1β release from macrophages, which may contribute to inflammation and chronic immune activation.